Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

The PROTAC (proteolysis-targeting chimera) ARV-825 recruits bromodomain and extraterminal (BET) proteins to the E3 ubiquitin ligase cereblon, leading to degradation of BET proteins, including BRD4. Whereas the BET-protein inhibitor (BETi) OTX015 caused accumulation of BRD4, treatment with equimolar...

Descripción completa

Detalles Bibliográficos
Autores principales: Saenz, Dyana T., Fiskus, Warren, Qian, Yimin, Manshouri, Taghi, Rajapakshe, Kimal, Raina, Kanak, Coleman, Kevin G., Crew, Andrew P., Shen, Angela, Mill, Christopher P., Sun, Baohua, Qiu, Peng, Kadia, Tapan M., Pemmaraju, Naveen, DiNardo, Courtney, Kim, Mi-Sun, Nowak, Agnieszka J., Coarfa, Cristian, Crews, Craig M., Verstovsek, Srdan, Bhalla, Kapil N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537055/
https://www.ncbi.nlm.nih.gov/pubmed/28042144
http://dx.doi.org/10.1038/leu.2016.393

Ejemplares similares

Ejemplares similares